Nama's AI scorecard currently rates TransMedics Group Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TMDX's P/E ratio?

TransMedics Group trades at a trailing price-to-earnings ratio of 49.6.

When does TMDX report earnings?

TransMedics Group's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.46.

What is the TMDX price target?

The median analyst price target from 11 analysts is $100.00, with a range of $65.00 – $125.00.

Is TMDX Shariah compliant?

Nama's AAOIFI-style screen reads TransMedics Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

TransMedics Group (TMDX)

Healthcare · Medical Devices · NASDAQ

TransMedics Group (TMDX) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $3.06B, a trailing price-to-earnings ratio of 49.6 and a free-cash-flow yield of 3.9%. Over the most recent reported fiscal year, revenue grew 37.1%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Trailing · -35.1% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-50.2%

How far the last close sits under the highest price of the past five years.

Market cap	$3.06B
Trailing P/E	49.6
Price / book	5.9
Price / sales	4.6
FCF yield	3.9%
Dividend yield	—
Gross margin	58.7%
Operating margin	12.2%
Net margin	22.7%
Revenue growth (YoY)	+37.1%
Revenue growth (3-yr annual)	+86.4%
EPS growth (YoY)	+178.2%
FCF/share growth (YoY)	—
Beta	1.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

TMDX earnings

Next report: Mar 1, 2027 (Q4 2026, EPS estimate $0.46). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.51	$0.29	+75.9%	—
Q2 2026	Aug 4, 2026	$0.44	$0.48	-8.3%	$189.95M
Q1 2026	May 5, 2026	$0.30	$0.61	-50.8%	$173.93M
Q4 2025	Feb 24, 2026	$0.53	$0.37	+43.2%	$160.76M

TMDX analyst price target

Median target $100.00 from 11 analysts, ranging $65.00 – $125.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live TMDX data on Nama Insights →

TMDX FAQ

Is TMDX a buy?: Nama's AI scorecard currently rates TransMedics Group Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TMDX's P/E ratio?: TransMedics Group trades at a trailing price-to-earnings ratio of 49.6.
When does TMDX report earnings?: TransMedics Group's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.46.
What is the TMDX price target?: The median analyst price target from 11 analysts is $100.00, with a range of $65.00 – $125.00.
Is TMDX Shariah compliant?: Nama's AAOIFI-style screen reads TransMedics Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.